Chimeric and humanized antibodies to α5β1 integrin that modulate angiogenesis
View Patent ↗The present invention provides chimeric and humanized antibodies that specifically recognize α5β1 integrin, and methods for using the antibodies for reducing or inhibiting angiogenesis in a tissue. Also provided are methods of determining therapeutically acceptable doses of the antibodies and pharmaceutical compositions including the same.
1. A vector comprising a first nucleic acid sequence selected from the group consisting of SEQ ID NOs: 15, 19, 23, 27, and 29, and a second nucleic acid sequence selected from the group consisting of SEQ ID NOs: 17, 21, 24, and 30.
2. The vector of claim 1 , wherein the vector comprises the nucleic acid sequences SEQ ID NOs: 23 and 24.
3. The vector of claim 1 , wherein the vector comprises the nucleic acid sequences SEQ ID NOs: 27 and 24.
4. The vector of claim 1 , wherein the vector comprises the nucleic acid sequences SEQ ID NOs: 29 and 30.
5. An isolated cell transformed by an expression vector comprising a first nucleic acid sequence selected from the group consisting of SEQ ID NOs: 15, 19, 23, 27, and 29, and a second nucleic acid sequence selected from the group consisting of SEQ ID NOs: 17, 21, 24, and 30.
6. The cell of claim 5 , wherein the expression vector comprises the nucleic acid sequences of SEQ ID NOs: 23 and 24.
7. The cell of claim 5 , wherein the expression vector comprises the nucleic acid sequences of SEQ ID NOs: 27 and 24.
8. The cell of claim 5 , wherein the expression vector comprises the nucleic acid sequences of SEQ ID NOs: 29 and 30.
9. A vector comprising a nucleic acid sequence selected from the group consisting of SEQ ID NOs: 15, 19, 23, 27, and 29; or selected from the group consisting of SEQ ID NOs: 17, 21, 24, and 30.
10. A vector comprising a nucleic acid sequence encoding all of the complementary determining regions (CDRs) from SEQ ID NO: 15, 17, 19, or 21.
11. The vector of claim 10 , wherein the CDRs are from SEQ ID NOs: 15 and 17; or from SEQ ID NOs: 19 and 21.